Ignite Creation Date:
2024-10-26 @ 3:40 PM
Last Modification Date:
2024-10-26 @ 3:40 PM
Study NCT ID:
NCT06608537
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-09-19
Brief Title:
A Clinical Study Based on FAPI-PETCT Technology to Predict Pathological Complete Response After Neoadjuvant Chemoradiotherapy for MSS Rectal Cancer
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Single-center Single-arm Phase II Clinical Study Based on FAPI-PETCT Technology to Predict Pathological Complete Response After Neoadjuvant Chemoradiotherapy for MSS Rectal Cancer
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The combination of short course radiotherapy and immunotherapy helps to increase the proportion of pathological complete response after neoadjuvant therapy providing more patients with the opportunity for organ preservation However there is no accurate and unified cCR diagnostic standard in the world As a new radiotracer 68Ga-FAPI has been developed and used to target fibroblast activating protein and tumor matrix visualization which has the advantages of low background uptake high contrast few preparation requirements short post-injection interval and no influence on blood glucose Therefore we will invite you to participate in a clinical study to explore whether the PET parameters of 18F-FDG and 68Ga-FAPI-42 PETCT can be used to predict pathological responses after neoadjuvant therapy for locally advanced rectal cancer LARC The findings will help improve future treatment stratification of LARC help patients preserve organs and improve quality of life
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None